Cdr1 in focus: a personal reflection on multidrug transporter research

Area of Science:

• Mycology
• Antifungal Drug Resistance
• Molecular Biology

Background:

• Human pathogenic Candida species exhibit evolving drug resistance mechanisms, posing a significant health threat.
• Established resistance strategies include target modification, overexpression, and chromosome duplication.
• Permeability barriers, involving reduced import or increased efflux, are crucial for Candida's antifungal resistance.

Purpose of the Study:

• To provide a retrospective overview of antifungal research shifts since the identification of the CDR1 gene.
• To explore the role of membrane efflux transporters in Candida multidrug resistance.
• To investigate how reduced azole permeability influences antifungal susceptibility in Candida species.

Main Methods:

• Review of historical research and identification of the first multidrug transporter gene, CDR1 (Candida Drug Resistance 1).
• Analysis of genomic data revealing numerous drug resistance genes, particularly those encoding membrane efflux transporters.
• Examination of the impact of reduced drug permeability on antifungal susceptibility.

Main Results:

• The identification of CDR1 marked a significant shift in understanding antifungal resistance.
• Candida genomes possess multiple genes for efflux transporters that actively expel antifungal drugs.
• Reduced permeability across Candida cell membranes is a key factor influencing susceptibility to antifungal agents.

Conclusions:

• Antifungal research has evolved to focus on efflux pumps and permeability as critical resistance mechanisms.
• Understanding these mechanisms, particularly CDR1's role, is vital for developing new antifungal therapies.
• Targeting drug permeability represents a promising avenue for overcoming Candida drug resistance.